Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

GPR62 Inhibitors

GPR62, or G protein-coupled receptor 62, is part of a large family of cell surface receptors that play key roles in various physiological processes by transducing extracellular signals into cellular responses. These receptors are characterized by their seven-transmembrane domain architecture and are known to influence intracellular signaling cascades when activated by specific ligands. The expression of GPR62 is subject to precise regulatory control, as it is with many genes, which involves a complex interplay of transcriptional, post-transcriptional, and epigenetic mechanisms. The modulation of GPR62 expression can have significant effects on cellular function, though the full extent and biological context of these effects are areas of active investigation. Factors that can inhibit the expression of GPR62 may do so through direct or indirect interactions with these regulatory pathways, potentially leading to a decreased presence of the receptor on the cell surface and thus altering the cellular signaling landscape. A variety of chemical compounds have been identified that could potentially inhibit the expression of GPR62 by targeting the intricate machinery of gene regulation. Compounds like Trichostatin A and Vorinostat are known to inhibit histone deacetylases, enzymes that remove acetyl groups from histone proteins, leading to a more condensed chromatin state and reduced transcriptional activity of certain genes, including possibly GPR62. DNA methyltransferase inhibitors, such as 5-Azacytidine and Decitabine, can alter the methylation status of DNA at gene promoters, which may lead to the downregulation of gene expression. These compounds intercede at the epigenetic level, potentially reducing the transcription of genes like GPR62 by changing the accessibility of the DNA to the transcriptional machinery. Other inhibitors, like LY294002 and PD98059, act further downstream by targeting specific signaling pathways within the cell. LY294002, a PI3K inhibitor, and PD98059, a MEK inhibitor, may reduce GPR62 expression by altering the activity of transcription factors and signaling proteins that govern the transcription of the GPR62 gene. It is through these varied mechanisms that the expression of GPR62 could be subject to modulation by these chemicals, thereby providing insight into the regulation of this receptor's role in cellular communication.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A could downregulate GPR62 by inhibiting histone deacetylase activity, which would result in a more closed chromatin configuration at the GPR62 gene promoter, leading to decreased transcription.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This DNA methyltransferase inhibitor may disrupt the methylation pattern on the DNA where the GPR62 gene resides, resulting in reduced binding of methyl-CpG-binding domain proteins and a subsequent decrease in GPR62 transcription.

RG 108

48208-26-0sc-204235
sc-204235A
10 mg
50 mg
$128.00
$505.00
2
(1)

RG 108 might decrease GPR62 expression by specifically preventing the methylation of cytosine residues within the promoter region of the GPR62 gene, thereby removing repressive epigenetic marks that suppress gene transcription.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid may lead to the downregulation of GPR62 through the inhibition of class I and II histone deacetylases, which would enhance acetylation of histones near the GPR62 gene, paradoxically causing repression of transcription in some contexts.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$88.00
$208.00
24
(2)

MS-275 could decrease GPR62 expression by selectively inhibiting class I histone deacetylases, promoting a compact chromatin structure around the GPR62 promoter and reducing the accessibility for transcriptional machinery.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

By incorporating into DNA and trapping DNA methyltransferases, 5-Aza-2′-Deoxycytidine could lead to a reduction in GPR62 expression due to a failure to maintain methylation patterns at the GPR62 gene promoter during DNA replication.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$214.00
$622.00
1
(1)

Romidepsin may inhibit GPR62 expression by selectively targeting class I histone deacetylases, resulting in the accumulation of acetylated histones that are associated with silenced genes, including potentially the GPR62 gene.

Panobinostat

404950-80-7sc-208148
10 mg
$196.00
9
(1)

Panobinostat could broadly decrease GPR62 expression by inhibiting a wide range of histone deacetylases, leading to altered acetylation patterns on histones associated with the GPR62 gene, which could repress its transcription.

Chetomin

1403-36-7sc-202535
sc-202535A
1 mg
5 mg
$182.00
$661.00
10
(1)

Chetomin could attenuate GPR62 expression by disrupting the function of hypoxia-inducible factors that may be involved in the upregulation of GPR62 under hypoxic conditions, thus leading to a decreased expression level.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin may inhibit GPR62 expression by blocking the mTOR pathway, which is involved in the control of cell growth and protein synthesis; this blockade could lead to a general decrease in the transcription of certain genes, possibly including GPR62.